Correct Answer: D. FISH and PCR
This case presents classic chronic myeloid leukemia (CML): massive splenomegaly, extreme leukocytosis (150,000/µL), left shift with myeloblasts/myelocytes/metamyelocytes, and markedly elevated M:E ratio (18:1). While the clinical and morphologic findings are highly suggestive, FISH and PCR are the gold standard for definitive diagnosis because they detect the pathognomonic t(9;22) Philadelphia chromosome and BCR-ABL fusion gene. FISH (fluorescence in situ hybridization) directly visualizes the translocation on metaphase chromosomes, while reverse-transcription PCR amplifies the BCR-ABL transcript with near 100% sensitivity and specificity. In Indian practice, PCR-based BCR-ABL quantification is also the standard for monitoring treatment response and detecting imatinib resistance (as per NCCN and ASCO guidelines adopted in India). Morphology and LAP score alone cannot distinguish CML from leukemoid reaction or other myeloproliferative disorders; immunophenotyping shows myeloid maturation but lacks the molecular specificity needed for CML diagnosis. FISH/PCR provides both diagnostic certainty and prognostic stratification (e.g., major BCR-ABL variants), making it the most sensitive and specific investigation.
Why the other options are wrong
A. LAP score — LAP (leukocyte alkaline phosphatase) score is low in CML but normal/high in leukemoid reaction, making it useful for differential diagnosis but NOT diagnostic for CML itself. It cannot detect the Philadelphia chromosome or BCR-ABL fusion. LAP is a functional enzyme assay, not a molecular test, and lacks the sensitivity and specificity needed for definitive CML diagnosis. B. Flow cytometry — Flow cytometry (immunophenotyping) characterizes cell surface and cytoplasmic markers to confirm myeloid lineage and maturation stage, but cannot detect chromosomal translocations or fusion genes. It shows abnormal myeloid differentiation in CML but is non-specific—similar patterns occur in other myeloproliferative disorders. It is complementary, not diagnostic, for CML. C. Immunophenotyping — Immunophenotyping identifies cell populations and lineage but lacks molecular resolution for BCR-ABL detection. While it may show increased myeloid blasts or abnormal maturation, it cannot distinguish CML from acute myeloid leukemia or other myeloproliferative neoplasms. It is a morphologic/immunologic tool, not a molecular diagnostic test.
High-Yield Facts
- Philadelphia chromosome t(9;22) is present in >95% of CML cases and is the pathognomonic hallmark detectable only by FISH or PCR.
- BCR-ABL fusion gene produces a constitutively active tyrosine kinase; PCR quantification guides imatinib dosing and detects resistance mutations in Indian CML management.
- FISH sensitivity ~100% for t(9;22) detection; PCR is even more sensitive for minimal residual disease monitoring post-treatment.
- LAP score is low in CML (0–20 units) but normal/high in leukemoid reaction, useful for differential but not diagnostic.
- M:E ratio >10:1 with left shift and splenomegaly suggests CML, but morphology alone cannot confirm—molecular testing is mandatory.
- Imatinib resistance (e.g., T315I mutation) is detected by BCR-ABL kinase domain sequencing, requiring PCR-based molecular analysis.
Mnemonics
CML Diagnosis = PHIlosophical Approach Philadelphia chromosome (FISH) → High BCR-ABL (PCR) → Imatinib response. FISH/PCR confirm the diagnosis; LAP and morphology support but don't diagnose. **FISH-PCR for Fusion gene confirmation** FISH visualizes the translocation; PCR quantifies the fusion transcript. Together they are the gold standard for CML diagnosis and monitoring in Indian practice.
NBE Trap
NBE may lure students with "LAP score" (option A) because it is a classic CML differential tool taught in textbooks; however, LAP is not diagnostic—it only supports the diagnosis. Similarly, "immunophenotyping" (option C) sounds sophisticated but lacks molecular specificity for BCR-ABL, the true diagnostic hallmark.
Clinical Pearl
In Indian tertiary centers, FISH/PCR is routinely performed at CML diagnosis to confirm t(9;22) and establish baseline BCR-ABL transcript level; this baseline is critical for monitoring imatinib efficacy and detecting resistance mutations (e.g., T315I) that require dose escalation or switch to second-generation TKIs—a practice now standard in AIIMS and major cancer centers across India.
_Reference: Robbins Ch. 13 (Hematopoietic and Lymphoid Systems); Harrison Ch. 104 (Chronic Myeloid Leukemia); KD Tripathi Ch. 18 (Antineoplastic Drugs—imatinib context)_